- Previous Close
24.71 - Open
26.60 - Bid 24.73 x --
- Ask 24.76 x --
- Day's Range
24.60 - 25.85 - 52 Week Range
10.66 - 31.63 - Volume
6,991,780 - Avg. Volume
8,743,914 - Market Cap (intraday)
4.688B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.17 - Earnings Date --
- Forward Dividend & Yield 0.45 (1.82%)
- Ex-Dividend Date Jul 30, 2024
- 1y Target Est
--
Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid biomedicine intermediates. Its products include 9a-hydroxyandrostenedione, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tetraene, androstenedione, ketal, 3-ketal, norandrostenedione, and betamethasone epoxy hydrolyzate, as well as 1,4-androstenedione. The company was founded in 2002 and is based in Heze, China.
www.sitobiotech.comRecent News: 300583.SZ
View MorePerformance Overview: 300583.SZ
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300583.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300583.SZ
View MoreValuation Measures
Market Cap
4.69B
Enterprise Value
5.23B
Trailing P/E
66.33
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.04
Price/Book (mrq)
2.41
Enterprise Value/Revenue
4.66
Enterprise Value/EBITDA
143.73
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.08%
Return on Assets (ttm)
0.85%
Return on Equity (ttm)
-0.30%
Revenue (ttm)
1.12B
Net Income Avi to Common (ttm)
-838.17k
Diluted EPS (ttm)
-0.17
Balance Sheet and Cash Flow
Total Cash (mrq)
148.45M
Total Debt/Equity (mrq)
36.44%
Levered Free Cash Flow (ttm)
81.15M